[N:1]1([C:7]2[N:12]=[C:11]([CH2:13][C:14](=[O:33])[N:15]3[C:23]4[C:18](=[C:19](C5CCCN(CCC)C5)[CH:20]=[CH:21][CH:22]=4)[CH2:17][CH2:16]3)[NH:10][C:9](=[O:34])[CH:8]=2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.Cl.CN(C)[CH2:38][CH2:39][CH2:40]N=C=NCC.N1(C2N=C(CC([O-])=O)NC(=O)C=2)CCOCC1.[Na+]>CN(C)C=O.N1C=CC=CC=1>[N:1]1([C:7]2[N:12]=[C:11]([CH2:13][C:14](=[O:33])[N:15]3[C:23]4[CH:22]=[CH:21][CH:20]=[CH:19][C:18]=4[CH:17]4[CH2:38][CH2:39][CH2:40][CH:16]34)[NH:10][C:9](=[O:34])[CH:8]=2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1320 mg of 1,2,3,3a,4,8b-hexahydrocyclopenta[b]indole [reference example 7d] and 424 mg of N-[3-(dimethylamino)propyl]-N′-ethylcarbodiimide hydrochloride are added to a solution of 525 mg of sodium [4-(morpholin-4-yl)-6-oxo-1,6-dihydropyrimidin-2-yl]acetate (obtained in step 2d of example 1d) in 4 ml of N,N-dimethylformamide and 4 ml of pyridine. The reaction mixture is stirred at ambient temperature for 72 hours and then concentrated under reduced pressure. The residue is taken up in a mixture of water and ethyl acetate and the organic phase is washed successively with water, a 1M hydrochloric acid solution and water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue is triturated from methanol, filtered and washed with diisopropyl ether, so as to give 375 mg of 6-(morpholin-4-yl)-2-[2-oxo-2-(2,3,3a,8b-tetrahydrocyclopenta[b]indol-4(1H)-yl)ethyl]pyrimidin-4(3H)-one, the characteristics of which are the following:
Loading…